Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues

View ORCID ProfileMartin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, Sune Boris Nygård
doi: https://doi.org/10.1101/2022.06.02.22275920
Martin Friedrichsen
1Novo Nordisk A/S, Søborg, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martin Friedrichsen
  • For correspondence: mfrc{at}novonordisk.com
Lars Endahl
1Novo Nordisk A/S, Søborg, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik Flindt Kreiner
1Novo Nordisk A/S, Søborg, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Goldwater
2PAREXEL International, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Kankam
3Altasciences Clinical Kansas, Overland Park, KS, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Søren Toubro
1Novo Nordisk A/S, Søborg, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sune Boris Nygård
1Novo Nordisk A/S, Søborg, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Article usage

Article usage: June 2022 to July 2025

AbstractFullPdf
Jun 2022787108219
Jul 2022319118100
Aug 202218217569
Sep 20221798960
Oct 20221498445
Nov 202215112066
Dec 2022918148
Jan 20231217848
Feb 20236810262
Mar 20239211355
Apr 2023746933
May 2023568543
Jun 20238310941
Jul 202317820056
Aug 20239812461
Sep 20237811467
Oct 20237611748
Nov 20239519745
Dec 2023656931
Jan 2024368128
Feb 2024859440
Mar 2024757422
Apr 2024683720
May 2024753712
Jun 2024562023
Jul 2024552421
Aug 2024483630
Sep 2024602317
Oct 2024552119
Nov 2024412922
Dec 202441715
Jan 2025301716
Feb 2025381724
Mar 2025414639
Apr 20251104642
May 2025636148
Jun 2025423921
Jul 2025202215
Back to top
PreviousNext
Posted June 03, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues
Martin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, Sune Boris Nygård
medRxiv 2022.06.02.22275920; doi: https://doi.org/10.1101/2022.06.02.22275920
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issues
Martin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, Sune Boris Nygård
medRxiv 2022.06.02.22275920; doi: https://doi.org/10.1101/2022.06.02.22275920

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Therapeutics
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)